[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 50.16.125.253. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
June 1990

Interferon Gamma Therapy for Cutaneous Leishmaniasis

Author Affiliations

Turkish Health and Therapy Foundation Memorial Ahmet Örs Hospital Emek Ankara, Turkey

Arch Dermatol. 1990;126(6):831-832. doi:10.1001/archderm.1990.01670300131030
Abstract

To the Editor.—  Cutaneous leishmaniasis is caused by Leishmania tropica and is prevalent in tropical and subtropical zones of the world.The treatment may not always be satisfactory. Some cases may be refractory to chemotherapeutic agents, including pentavalent antimony drugs. In such cases, the persistence of the infection may be due to depression of antigen-specific cell-mediated immunity' and defects in macrophage functions.2-4We treated a patient with cutaneous leishmaniasis with a combination of interferon gamma and pentavalent antimony who failed to respond to two courses of methylglucamine antimonate (Glucantime) therapy previously.The patient received recombinant human inferferon (RU 42369, Roussel-UCLAF, Romainville, France) injections daily in a dose of 100 μg/m2 of body surface area. The dose of methylglucamine antimonate injections was 50 mg/kg per day. During the treatment, the following laboratory tests were performed: complete blood cell count with differential white blood cell count, urinalysis, and blood chemistry

First Page Preview View Large
First page PDF preview
First page PDF preview
×